A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs CB 839 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 07 Aug 2017 Status changed from not yet recruiting to recruiting, according to a Calithera Biosciences media release.
    • 02 Jun 2017 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
    • 02 Jun 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top